Similar articles

• [Levofloxacin in complex therapy of patients with skin and soft tissue infections].

  Blatun LA, Terekhova RP. Blatun LA, et al. Antibiot Khimioter. 2008;53(9-10):32-5. Antibiot Khimioter. 2008. PMID: 19441647 Review. Russian. No abstract available.
• [Efficacy and safety of levofloxacin in low respiratory tract infection].

  Zubkov MN. Zubkov MN. Antibiot Khimioter. 2004;49(5):31-7. Antibiot Khimioter. 2004. PMID: 15573900 Review. Russian. No abstract available.
• Moxifloxacin: new preparation. A me-too with more cardiac risks.

  [No authors listed] [No authors listed] Prescrire Int. 2002 Dec;11(62):168-9. Prescrire Int. 2002. PMID: 12469694
• Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study.

  Tarshis GA, Miskin BM, Jones TM, Champlin J, Wingert KJ, Breen JD, Brown MJ. Tarshis GA, et al. Antimicrob Agents Chemother. 2001 Aug;45(8):2358-62. doi: 10.1128/AAC.45.8.2358-2362.2001. Antimicrob Agents Chemother. 2001. PMID: 11451697 Free PMC article. Clinical Trial.
• Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

  Langtry HD, Lamb HM. Langtry HD, et al. Drugs. 1998 Sep;56(3):487-515. doi: 10.2165/00003495-199856030-00013. Drugs. 1998. PMID: 9777318 Review.